Table I.
Characteristics of the patients (n=44) with radiotherapy for bone metastasis (n=29) or without radiotherapy (n=15).
| Variable | All patients | Radiotherapy for bone metastasis | No radiotherapy for bone metastasis | P-value |
|---|---|---|---|---|
| Age at diagnosis of bone metastasis, years | 66 (39–83) | 65 (39–83) | 63 (43–76) | 0.911 |
| Sex | ||||
| Male | 32 (73) | 22 (76) | 10 (66) | 1.000 |
| Female | 12 (27) | 7 (24) | 5 (34) | |
| IMDC risk stratification | ||||
| Favorable | 11 (25) | 7 (24) | 4 (27) | 0.854 |
| Intermediate | 23 (52) | 16 (55) | 7 (46) | |
| Poor | 10 (23) | 6 (21) | 4 (27) | |
| Histology | ||||
| Clear cell | 37 (84) | 24 (83) | 13 (86) | 1.000 |
| Non-clear cell | 7 (16) | 5 (17) | 2 (14) | |
| Nephrectomy | ||||
| Yes | 36 (82) | 25 (86) | 11 (73) | 0.414 |
| No | 8 (18) | 4 (14) | 4 (27) | |
| Metastasis at the diagnosis of RCC | ||||
| Bone metastasis with or without extraosseous metastasis | 22 (50) | 15 (52) | 7 (46) | 0.935 |
| Extraosseous metastasis only | 6 (14) | 4 (14) | 2 (14) | |
| No metastasis | 16 (36) | 10 (34) | 6 (40) | |
| Multiplicity of bone metastasis | ||||
| Solitary | 19 (43) | 12 (41) | 7 (46) | 0.737 |
| Multiple | 25 (57) | 17 (59) | 8 (54) | |
| Bone-modifying agents | ||||
| Yes | 17 (39) | 15 (52) | 2 (14) | 0.021 |
| No | 27 (61) | 14 (48) | 13 (86) | |
| Systemic therapy after diagnosis of bone metastasis | ||||
| Sunitinib | 24 (56) | 14 (48) | 10 (66) | 0.110 |
| Axitinib | 3 (7) | 1 (4) | 2 (14) | |
| Pazopanib | 3 (7) | 3 (10) | 0 | |
| Sorafenib | 2 (4) | 2 (7) | 0 | |
| Temsirolimus | 2 (4) | 2 (7) | 0 | |
| Everolimus | 2 (4) | 0 | 2 (14) | |
| Nivolumab | 4 (9) | 3 (10) | 1 (6) | |
| Nivolumab, Ipilimumab | 4 (9) | 4 (14) | 0 |
Data are presented as the median (interquartile range) or a n (%). RCC, renal cell carcinoma; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium.